October 2020

Encouraging Results for Palbociclib Plus Fulvestrant for Metastatic Breast Cancer 
According to results from the phase ll FLIPPER trial presented at the recent European Society of Medical Oncology Virtual Congress 2020, 1-year progression-free survival in the first-line treatment of hormone receptor-positive, HER2-negative metastatic breast cancer was considerably longer for those patients treated with fulvestrant plus the CDK4/6 inhibitor palbociclib compared with fulvestrant plus placebo. Read more.


Promising Results With Atezolizumab Plus Chemotherapy in Triple Negative Breast Cancer 
Findings from the phase lll IMpassion031 trial presented at the ESMO Virtual Congress 2020 and published in The Lancet indicate that combining atezolizumab with standard neoadjuvant chemotherapy achieves substantially greater pathologic complete response rates than chemotherapy alone in individuals with stage II or III triple-negative breast cancer. Read more.

New First-Line Treatment Leads to Improved Survival in Gastrointestinal Cancers 
Interim results from the phase lll CheckMate 649 trial presented at the 2020 European Society of Medical Oncology Virtual Congress revealed that first-line treatment of gastric, gastroesophageal junction, and esophageal cancers with nivolumab plus chemotherapy prolonged progression-free survival and overall survival compared with chemotherapy alone. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App